Peptide news FAQ

Substitute with tirzepatide or mazdutide as a dual agonist comparator while you wait, and document the mechanistic differences explicitly in your methods section. Retatrutide's triple agonism includes glucagon receptor activity that tirzepatide (GLP-1/GIP dual agonist) lacks, so thermogenesis and hepatic glucose output endpoints will differ. If your hypothesis centers specifically on triple agonism, delay the study. Using a dual agonist proxy and extrapolating conclusions about triple agonism will fail peer review. If your hypothesis tests incretin receptor crosstalk broadly, tirzepatide provides 80% mechanistic overlap and is available now.